The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses

Z Al Kanaani, S Mahmud… - Royal Society …, 2018 - royalsocietypublishing.org
To characterize hepatitis C virus (HCV) epidemiology in Pakistan and estimate the pooled
mean HCV antibody prevalence in different risk populations, we systematically reviewed all …

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar

…, HH Ayoub, Z Al Kanaani, E Al Kuwari… - … England Journal of …, 2021 - Mass Medical Soc
Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The …

Effects of previous infection and vaccination on symptomatic omicron infections

…, P Coyle, Z Al-Kanaani, E Al-Kuwari… - … England Journal of …, 2022 - Mass Medical Soc
Background The protection conferred by natural immunity, vaccination, and both against
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the …

Protection against the Omicron variant from previous SARS-CoV-2 infection

…, Z Al-Kanaani, E Al-Kuwari… - … England Journal of …, 2022 - Mass Medical Soc
Protection against Omicron by Previous SARS-CoV-2 Infection Using a national Covid-19
database in Qatar, investigators found that previous SARS-CoV-2 infection provided protection …

Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar

…, P Coyle, Z Al-Kanaani, E Al-Kuwari… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19)
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …

mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar

…, P Coyle, HH Ayoub, Z Al Kanaani, E Al Kuwari… - Nature medicine, 2021 - nature.com
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar

…, MR Hasan, Z Al-Kanaani, E Al-Kuwari… - Nature …, 2022 - nature.com
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted
a matched, test-negative, case-control study to estimate duration of protection of the second …

Protective effect of previous SARS-CoV-2 infection against Omicron BA. 4 and BA. 5 subvariants

…, HA Al-Khatib, MK Smatti, Z Al-Kanaani… - … England Journal of …, 2022 - Mass Medical Soc
Al-Romaihi, MD … Al-Thani, MD … Ayoub HH, Tomy M, Chemaitelly H, et al. Estimating
protection afforded by prior infection in preventing reinfection: applying the test-negative …

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

…, P Coyle, HH Ayoub, Z Al Kanaani, E Al Kuwari… - Nature medicine, 2021 - nature.com
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant,
we conducted a matched test-negative case–control study to assess the real-world …

[HTML][HTML] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

…, HH Ayoub, Z Al Kanaani, E Al Kuwari… - …, 2021 - thelancet.com
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …